Literature DB >> 16784015

Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.

K Demirkan1, B Bozkurt, G Karakaya, A F Kalyoncu.   

Abstract

Proton pump inhibitors and H2 receptor antagonists, which are commonly used to treat peptic ulcer and gastroesophageal reflux diseases, are associated with a low incidence of adverse reactions. We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period. Cutaneous sensitivity to famotidine, ranitidine, omeprazole, pantoprazole, and lansoprazole was evaluated by skin prick tests with a concentration of 10 mg/mL (at 1:1000, 1:100, 1:10 and 1:1 dilutions), and if they were negative, intradermal skin tests were performed with the same dilutions of the extracts. Single-blind, placebo-controlled oral provocation tests were performed with lansoprazole, omeprazole, famotidine, and ranitidine in 2 cases. One case involved anaphylaxis during an oral provocation test with lansoprazole, and 2 cases were anaphylactic reactions to ranitidine. In both cases the skin test was positive for ranitidine and in 1 case an oral provocation test was also positive. The second patient refused that test. Cross reactivity to other H2 receptor antagonists was not demonstrated and a safe alternative drug was found for all 3 patients. Although incidences of anaphylactic reactions induced by proton pump inhibitors or H2 reactions are rare, they can be life threatening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784015

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  16 in total

1.  Ranitidine-Induced Anaphylaxis in a Patient with Acute COPD Exacerbation.

Authors:  İnsu Yılmaz; Murat Türk
Journal:  Turk Thorac J       Date:  2017-07-01

Review 2.  The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.

Authors:  Neehar Parikh; Colin W Howden
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

3.  Anaphylaxis following intravenous ranitidine: a rare adverse reaction of a common drug.

Authors:  Deepti Chopra; Pooja Arora; Shamimullah Khan; Shridhar Dwivedi
Journal:  Indian J Pharmacol       Date:  2014 Mar-Apr       Impact factor: 1.200

Review 4.  Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.

Authors:  Iris M Otani; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

5.  Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.

Authors:  Woo-Jung Song; Min-Hye Kim; Sang-Min Lee; Yong-Eun Kwon; Sae-Hoon Kim; Sang-Heon Cho; Kyung-Up Min; You-Young Kim; Yoon-Seok Chang
Journal:  Allergy Asthma Immunol Res       Date:  2010-09-06       Impact factor: 5.764

6.  Ranitidine anaphylaxis: A rare occurrence.

Authors:  Varsha H Vyas; Shubha N Mohite; Sonal S Khatavkar; Sheetal R Jagtap
Journal:  Indian J Anaesth       Date:  2011-07

7.  The added value of H2 antagonists in premedication regimens during paclitaxel treatment.

Authors:  Juul M Cox; Leni van Doorn; Ruben Malmberg; Esther Oomen-de Hoop; Tessa M Bosch; Patricia M L A van den Bemt; Ingrid A Boere; Agnes Jager; Ron H J Mathijssen; Roelof W F van Leeuwen
Journal:  Br J Cancer       Date:  2021-03-24       Impact factor: 9.075

8.  Intraoperative anaphylaxis to ranitidine during cesarean section.

Authors:  R Sripriya; V R Hemanth Kumar; Rajesh Prabhu; M Ravishankar
Journal:  J Nat Sci Biol Med       Date:  2013-01

9.  Anaphylactic reaction associated with Ranitidine in a patient with acute pancreatitis: a case report.

Authors:  Ulfin Rethnam; Rajam Sheeja Yesupalan
Journal:  J Med Case Rep       Date:  2007-08-31

10.  Fatal injection of ranitidine: a case report.

Authors:  Antonio Oliva; Sara Partemi; Vincenzo Arena; Fabio De Giorgio; Catia Colecchi; Nadia Fucci; Vincenzo L Pascali
Journal:  J Med Case Rep       Date:  2008-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.